NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options

Hot Topics of the Day|PHGKB

 Coronavirus

NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
NIH, April 17, 2020 

Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.

Characterizing geographical and temporal dynamics of novel coronavirus SARS-CoV-2 using informative subtype markers
Z Zhao et al, BIORXIV, April 16, 2020

Investigating the genomic landscape in novel coronavirus (2019-nCoV) genomes to identify non-synonymous mutations for use in diagnosis and drug design
P Tiwari et al, MEDRXIV, April 18, 2020

Modeling COVID-19 latent prevalence to assess a public health intervention at a state and regional scale
PJ Turk et al, MEDRXIV, April 18, 2020

Broad Host Range of SARS-CoV-2 Predicted by Comparative and Structural Analysis of ACE2 in Vertebrates
J Damas, et al, BIORXIV, April 18, 2020

Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-qPCR
I Smyrlaki et al, MEDRXIV, April 17, 2020

CoroNet: A Deep Network Architecture for Semi-Supervised Task-Based Identification of COVID-19 from Chest X-ray Images
S Khobahi et al, MEDRXIV, April 17, 2020

We establish the use of a rapid, non-invasive and cost-effective X-ray-based method as a key diagnosis and screening tool for COVID-19 at early and intermediate stages of the disease. We develop a novel and sophisticated deep learning-based signal and image processing technique as well as classification methodology for analyzing X-ray images.

Association of inflammatory markers with the severity of COVID-19
F Zeng et al, MEDRXIV, April 1, 2020

16 studies were included comprising 3962 patients with COVID-19. Non-severe COVID-19 patients had lower levels for CRP, PCT, IL-6, ESR, SAA and serum ferritin. Moreover, survivors had lower level for IL-6 than non-survivors. This meta-analysis highlights the association of inflammatory markers with the severity of COVID-19.